Sector
PharmaceuticalsOpen
₹79.96Prev. Close
₹79.17Turnover(Lac.)
₹11.66Day's High
₹81.49Day's Low
₹79.9652 Week's High
₹144.9952 Week's Low
₹70.1Book Value
₹94.31Face Value
₹10Mkt Cap (₹ Cr.)
127.12P/E
18.46EPS
4.37Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 15.83 | 15.83 | 15.83 | 15.83 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 126.52 | 136.13 | 134.73 | 114.96 |
Net Worth | 142.35 | 151.96 | 150.56 | 130.79 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 380.14 | 282.35 | 279.37 | 302.88 |
yoy growth (%) | 34.63 | 1.06 | -7.76 | 2.66 |
Raw materials | -251.78 | -195.34 | -163.36 | -197.47 |
As % of sales | 66.23 | 69.18 | 58.47 | 65.19 |
Employee costs | -29.87 | -26.04 | -22.98 | -19.07 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 39.51 | 6.25 | 29.34 | 31.18 |
Depreciation | -9.17 | -8.21 | -6.56 | -5 |
Tax paid | -11.54 | 2 | -9.45 | -8.9 |
Working capital | 27.78 | -24.07 | 15.15 | -3.81 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 34.63 | 1.06 | -7.76 | 2.66 |
Op profit growth | 124.95 | -49.44 | 2.07 | 22.36 |
EBIT growth | 193.24 | -59.49 | -0.21 | 23.74 |
Net profit growth | 238.93 | -58.5 | -10.7 | 38.93 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 |
---|---|---|
Gross Sales | 317.58 | 367.35 |
Excise Duty | 0 | 0 |
Net Sales | 317.58 | 367.35 |
Other Operating Income | 0.65 | 1.24 |
Other Income | 0.5 | 0.1 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Govardhan M Dhoot
Whole-time Director
Brijmohan Dhoot
Independent Director
Rukmesh P. Dhandhania
Independent Director
Nidhi S. Mundada
Independent Director
Praveen Saxena
Non Executive Director
Rakesh K. Milwani
Company Sec. & Compli. Officer
Anuradha Pandey
3rd Floor Rupam Building,
239 P D Mello Road,
Maharashtra - 400001
Tel: 91-22-22616200/6300/8787
Website: http://www.mangalamdrugs.com
Email: [email protected]
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: [email protected]
Summary
Mangalam Drugs and Organics Ltd was formerly incorporated on April 18, 1972 as a private limited company with the name Advent Pharma Pvt Ltd. On July 1, 1997, the Company changed their name from Adven...
Read More
Reports by Mangalam Drugs and Organics Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.